RxDoctor Payments DataLook up a doctor →

Zoltan Mari, MD

Neurology · Las Vegas, NVNPI 1366480048

Payments from drug & device makers

$1,384,161in general payments, 2019–2025

Across 885 payments — averaging $1564.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$537K
  • Acadia Pharmaceuticals Inc$293K
  • Eli Lilly$232K
  • MDD US Operations, LLC$108K
  • Amneal Pharmaceuticals LLC$106K
  • Global Kinetics USA Corporation$64K
  • plus $44K from 20 others
$50,807in research payments, 2019–2025

Across 9 payments — averaging $5645.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$26K
  • Amneal Pharmaceuticals LLC$24K
  • Eli Lilly$50

What the payments were for

  • Consulting fees$142,32223%
  • Speaking & faculty fees$420,86767%
  • Travel & lodging$42,2777%
  • Food & beverage$23,0534%
  • Education$2730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384,161 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$351,411
Medicare patients
305
Services billed
37,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa161$362,595
NuplazidPimavanserin Tartrate47$230,354
GocovriAmantadine Hcl22$60,017
XadagoSafinamide Mesylate22$26,103
Carbidopa-LevodopaCarbidopa/Levodopa210$8,630
Rasagiline Mesylate24$5,452
Carbidopa-Levodopa ErCarbidopa/Levodopa54$3,195
AmantadineAmantadine Hcl26$1,806
Propranolol Hcl ErPropranolol Hcl24$1,079
Fludrocortisone Acetate20$928
Clonazepam54$829
Propranolol Hcl37$724
Ropinirole ErRopinirole Hcl15$707
Quetiapine Fumarate35$698
Primidone25$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$106,206$362,595161 claims
Acadia Pharmaceuticals IncNuplazid$292,960$230,35447 claims
MDD US Operations, LLCGocovri$107,734$60,01722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →